TEVA-TOLTERODINE LA DIN 02412209
Health Canada record
| Active ingredient(s) | TOLTERODINE TARTRATE 4 MG |
|---|---|
| Dosage form | Capsule (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | G04BD07 TOLTERODINE |
| Original market date | 16-Dec-2015 |
| Current status date | 16-Dec-2015 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TOLTERODINE TARTRATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02239064 | DETROL | BGP PHARMA ULC | Tablet | TOLTERODINE TARTRATE 1 MG | Marketed |
| 02239065 | DETROL | BGP PHARMA ULC | Tablet | TOLTERODINE TARTRATE 2 MG | Marketed |
| 02244612 | DETROL LA | BGP PHARMA ULC | Capsule (Extended-Release) | TOLTERODINE TARTRATE 2 MG | Marketed |
| 02244613 | DETROL LA | BGP PHARMA ULC | Capsule (Extended-Release) | TOLTERODINE TARTRATE 4 MG | Marketed |
| 02496844 | JAMP TOLTERODINE | JAMP PHARMA CORPORATION | Tablet | TOLTERODINE TARTRATE 2 MG | Marketed |
| 02496836 | JAMP TOLTERODINE | JAMP PHARMA CORPORATION | Tablet | TOLTERODINE TARTRATE 1 MG | Marketed |
| 02423316 | MINT-TOLTERODINE | MINT PHARMACEUTICALS INC | Tablet | TOLTERODINE TARTRATE 2 MG | Marketed |
| 02423308 | MINT-TOLTERODINE | MINT PHARMACEUTICALS INC | Tablet | TOLTERODINE TARTRATE 1 MG | Marketed |
| 02413140 | SANDOZ TOLTERODINE LA | SANDOZ CANADA INCORPORATED | Capsule (Extended-Release) | TOLTERODINE TARTRATE 2 MG | Marketed |
| 02413159 | SANDOZ TOLTERODINE LA | SANDOZ CANADA INCORPORATED | Capsule (Extended-Release) | TOLTERODINE TARTRATE 4 MG | Marketed |
| 02299607 | TEVA-TOLTERODINE | TEVA CANADA LIMITED | Tablet | TOLTERODINE TARTRATE 2 MG | Marketed |
| 02299593 | TEVA-TOLTERODINE | TEVA CANADA LIMITED | Tablet | TOLTERODINE TARTRATE 1 MG | Marketed |
| 02412195 | TEVA-TOLTERODINE LA | TEVA CANADA LIMITED | Capsule (Extended-Release) | TOLTERODINE TARTRATE 2 MG | Marketed |
| 02451875 | ACH-TOLTERODINE TARTRATE EXTENDED RELEASE | ACCORD HEALTHCARE INC | Capsule (Extended-Release) | TOLTERODINE TARTRATE 4 MG | Cancelled Pre Market |
| 02451867 | ACH-TOLTERODINE TARTRATE EXTENDED RELEASE | ACCORD HEALTHCARE INC | Capsule (Extended-Release) | TOLTERODINE TARTRATE 2 MG | Cancelled Pre Market |
| 02369680 | APO-TOLTERODINE | APOTEX INC | Tablet | TOLTERODINE TARTRATE 1 MG | Cancelled Post Market |
| 02369699 | APO-TOLTERODINE | APOTEX INC | Tablet | TOLTERODINE TARTRATE 2 MG | Cancelled Post Market |
| 02377330 | GD-TOLTERODINE | GENMED A DIVISION OF PFIZER CANADA ULC | Tablet | TOLTERODINE TARTRATE 1 MG | Cancelled Pre Market |
| 02377349 | GD-TOLTERODINE | GENMED A DIVISION OF PFIZER CANADA ULC | Tablet | TOLTERODINE TARTRATE 2 MG | Cancelled Pre Market |
| 02377365 | GD-TOLTERODINE LA | GENMED A DIVISION OF PFIZER CANADA ULC | Capsule (Extended-Release) | TOLTERODINE TARTRATE 2 MG | Cancelled Pre Market |
| 02377357 | GD-TOLTERODINE LA | GENMED A DIVISION OF PFIZER CANADA ULC | Capsule (Extended-Release) | TOLTERODINE TARTRATE 4 MG | Cancelled Pre Market |
| 02404192 | MYLAN-TOLTERODINE ER | MYLAN PHARMACEUTICALS ULC | Capsule (Extended-Release) | TOLTERODINE TARTRATE 4 MG | Cancelled Post Market |
| 02404184 | MYLAN-TOLTERODINE ER | MYLAN PHARMACEUTICALS ULC | Capsule (Extended-Release) | TOLTERODINE TARTRATE 2 MG | Cancelled Post Market |
| 02430002 | RAN-TOLTERODINE | RANBAXY PHARMACEUTICALS CANADA INC. | Tablet | TOLTERODINE TARTRATE 2 MG | Cancelled Pre Market |
| 02429993 | RAN-TOLTERODINE | RANBAXY PHARMACEUTICALS CANADA INC. | Tablet | TOLTERODINE TARTRATE 1 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 17565 | 2015-12-16 | Abbreviated New Drug Submission (ANDS) |
International API supply for TOLTERODINE TARTRATE
7 valid EDQM Certificates of Suitability from 7 holders. 15 active FDA Drug Master Files.
Request a quote for TEVA-TOLTERODINE LA